{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:19:49Z","timestamp":1777670389001,"version":"3.51.4"},"reference-count":8,"publisher":"SAGE Publications","issue":"11-12","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1089\/hum.2023.29243.bfs","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T10:54:39Z","timestamp":1687258479000},"page":"477-480","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Food and Drug Administration Sets Stage for Approval of First Duchenne Muscular Dystrophy Gene Therapy"],"prefix":"10.1177","volume":"34","author":[{"given":"Alex","family":"Philippidis","sequence":"first","affiliation":[{"name":"Mary Ann Liebert, Inc., Publishers, New Rochelle, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"e_1_3_1_2_2","unstructured":"Sarepta Therapeutics. Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy. 2023. Available from: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-positive-vote-us-fda-advisory [Last accessed: May13 2023]."},{"key":"e_1_3_1_3_2","unstructured":"Scribe Therapeutics. Scribe Announces Collaboration with Prevail a Wholly Owned Subsidiary of Lilly to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases. May 16 2023. Available from: https:\/\/www.scribetx.com\/press-release-scribe-announces-collaboration-with-prevail-a-wholly-owned-subsidiary-of-lilly-to-accelerate-in-vivo-crispr-based-genetic-medicines-for-neurological-and-neuromuscular-diseases\/ [Last accessed: May16 2023]."},{"key":"e_1_3_1_4_2","unstructured":"Massachusetts Workforce Development System (MassHire). Worker Adjustment and Retraining Act (WARN) weekly report. Week ending May 5 2023. Available from: https:\/\/www.mass.gov\/service-details\/worker-adjustment-and-retraining-act-warn-weekly-report [Last accessed: May12 2023]."},{"key":"e_1_3_1_5_2","unstructured":"Waldron J. Takeda confirms fallout from gene therapy R&D refocus: up to 186 layoffs. FierceBiotech 2023. Available from: https:\/\/www.fiercebiotech.com\/biotech\/takeda-confirms-fallout-gene-therapy-rd-refocus-186-redundancies [Last accessed: May12 2023]."},{"key":"e_1_3_1_6_2","unstructured":"Taysha Gene Therapies. Form 8-K April 27 2023. Taysha Gene Therapies Inc.: Dallas TX. Available from: https:\/\/ir.tayshagtx.com\/static-files\/b9c68527-cdef-4102-a250-a47c4e4aa9e6 [Last accessed: May11 2023]."},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","unstructured":"Philippidis A. Taysha Faces Stock Delisting Scraps $75M Durham Manufacturing Facility. 2023. Available from: https:\/\/www.genengnews.com\/topics\/genome-editing\/gene-therapy\/taysha-faces-stock-delisting-scraps-75m-durham-manufacturing-facility\/ [Last accessed: May11 2023].","DOI":"10.1089\/genedge.5.1.70"},{"key":"e_1_3_1_8_2","unstructured":"Ascend Gene & Cell Therapies. Gene & Cell Therapy Manufacturing Specialist Ascend Launches with Over $130M of Funding as Expert Teams Merge. 2023. Available from https:\/\/static1.squarespace.com\/static\/61eabe036a52cb117905aca8\/t\/645ba1bc07ba28045e7e577d\/1683726780991\/Ascend+press+release.pdf [Last accessed: May12 2023]."},{"key":"e_1_3_1_9_2","unstructured":"Bluebird Bio. Bluebird bio Submits Biologics License Application (BLA) to FDA for Lovotibeglogene Autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 Years and Older with a History of Vaso-Occlusive Events. 2023. Available from https:\/\/investor.bluebirdbio.com\/news-releases\/news-release-details\/bluebird-bio-submits-biologics-license-application-bla-fda-0 [Last accessed: May11 2023]."}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2023.29243.bfs","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2023.29243.bfs","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2023.29243.bfs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:56:36Z","timestamp":1777449396000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2023.29243.bfs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":8,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1089\/hum.2023.29243.bfs"],"URL":"https:\/\/doi.org\/10.1089\/hum.2023.29243.bfs","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}